<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671942</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ-01459-IIA</org_study_id>
    <nct_id>NCT02671942</nct_id>
  </id_info>
  <brief_title>A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetics of different dose roflumilast in China COPD&#xD;
      patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Roflumilast is a product which has been approved for the treatment of severe chronic&#xD;
      obstructive lung disease (COPD) and its approved dose is 500μg once daily. This study is&#xD;
      primarily designed to see whether alternation in this dose can improve tolerability of&#xD;
      Roflumilast in COPD patients. Therefore one in three patients will start roflumilast therapy&#xD;
      at a lower dose of 250μg/375μg once daily, another one in three will only take the 500μg&#xD;
      tablet every day (and one placebo every day). Furthermore, the study will evaluate the safety&#xD;
      and pharmacokinetics of different dose roflumilast in China COPD patient.&#xD;
&#xD;
      Lastly, the study will investigate what the body does to roflumilast. Patients with a history&#xD;
      of COPD for at least last 12 months and a former smoker or current smoker with history of at&#xD;
      least 10 pack years will be invited to participate.&#xD;
&#xD;
      The Randomization visit is considered the Baseline visit and for participants that&#xD;
      discontinue the Main Period and continue into the Down-Titration Period Day 1 of Down&#xD;
      Titration is considered BaselineDT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">June 13, 2018</completion_date>
  <primary_completion_date type="Actual">June 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentrationafter versus drug dose</measure>
    <time_frame>baseline to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events of Interest</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Adverse events of interest to evaluate tolerability are defined as diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) during the down titration period</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing will be performed using spirometry prior to taking study medication</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>roflumilast:250μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Roflumilast Roflumilast tablets Roflumilast 250 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>roflumilast:375μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Roflumilast Roflumilast tablets Roflumilast 375 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>roflumilast:500μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Roflumilast Roflumilast tablets Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: placebo placebo tablets placebo tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <arm_group_label>roflumilast:250μg</arm_group_label>
    <arm_group_label>roflumilast:375μg</arm_group_label>
    <arm_group_label>roflumilast:500μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is male or female and aged 40 or olderThe BMI≥ 19.0 kg/m2;&#xD;
&#xD;
          2. The patient with severe to very severe COPD as difine by the 2015 Gold strategy&#xD;
             .(postbronchodilator ≤0.7,，and a postbronchodilator FEV1≤50% predicted);&#xD;
&#xD;
          3. Has a history of chronic obstructive pulmonary disease (COPD) (according to Global&#xD;
             Initiative for Chronic Obstructive Lung Disease (GOLD) 2015) for at least 12 months&#xD;
             prior to Screening (Visit V0), At least two documented moderate or severe COPD&#xD;
             exacerbations within 12 months prior to Screening (Visit 0);&#xD;
&#xD;
          4. Must be a former smoker (defined as smoking cessation at least one year ago) or&#xD;
             current smoker both with a smoking history of at least 10 pack years;&#xD;
&#xD;
          5. Women of childbearing age must take reliable contraceptive measures&#xD;
&#xD;
          6. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe or very severe COPD exacerbations is still exist in screen visit(V0);&#xD;
&#xD;
          2. Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit V0;&#xD;
&#xD;
          3. History of asthma diagnosis in patients &lt; 40 years of age or relevant lung disease&#xD;
             other than COPD;&#xD;
&#xD;
          4. relevant lung disease other than COPD,as: Bronchiectasis, Cystic fibrosis, capillary&#xD;
             bronchitis, lung resection, lung cancer, interstitial lung disease and active&#xD;
             tuberculosis&#xD;
&#xD;
          5. Current participation in a pulmonary rehabilitation program or completion of a&#xD;
             pulmonary rehabilitation program within 3 months preceding the baseline visit V0&#xD;
&#xD;
          6. Known alpha-1-antitrypsin deficiency;&#xD;
&#xD;
          7. Clinically significant abnormal Laboratory examination,may due to one Undiagnosed&#xD;
             disease&#xD;
&#xD;
          8. The patient with severe Mental or neurological disease;&#xD;
&#xD;
          9. Has a history with Suicidal ideation or depression;&#xD;
&#xD;
         10. Congestive heart failure New York Heart Association Functional Classification (NYHA)&#xD;
             severity grade III-IV;&#xD;
&#xD;
         11. Used disabled combination medicine;&#xD;
&#xD;
         12. A serious autoimmune disease;&#xD;
&#xD;
         13. Liver dysfunction according to Child-Pugh B/C;&#xD;
&#xD;
         14. Serious acute Infectious diseases;&#xD;
&#xD;
         15. Has a history Malignant in the last 5 years;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>roflumilast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Have no plan to make individual participant data available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

